Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Outpatients With Stable Coronary Artery Disease  by Hamon, Martial et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 4 , N O . 1 4 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 7 . 9 5 7Incidence, Source, Determinants, and
Prognostic Impact of Major Bleeding
in Outpatients With Stable Coronary
Artery Disease
Martial Hamon, MD,*y Gilles Lemesle, MD,zxk Olivier Tricot, MD,{ Thibaud Meurice, MD,# Michel Deneve,z
Xavier Dujardin, MD,** Jean Michel Brufau, MD,yy Jerome Bera, MD,# Nicolas Lamblin, MD,zxk
Christophe Bauters, MDzxkABSTRACTFro
tal
Fra
Bo
Va
tha
Lis
Yo
MaBACKGROUND Although there is evidence that patients who experience major bleeding after an acute coronary event
are at higher risk of death in the months after the event, the incidence and impact on outcome of bleeding beyond 1 year
of follow-up in patients with stable coronary artery disease (CAD) are largely unknown.
OBJECTIVES The goal of this study was to assess the incidence, source, determinants, and prognostic impact of major
bleeding in stable CAD.
METHODS We prospectively included 4,184 consecutive CAD outpatients who were free from any myocardial infarction
(MI) or coronary revascularization for >1 year at inclusion. Follow-up was performed at 2 years, with major bleeding
deﬁned as a type $3 bleed using the Bleeding Academic Research Consortium (BARC) deﬁnition.
RESULTS There were 51 major bleeding events during follow-up (0.6%/year). Most events were BARC type 3a bleeds
with 12 fatal bleeds (type 5). In most cases (54.9%), the site of bleeding was gastrointestinal. Major bleeding was
signiﬁcantly associated with mortality (adjusted hazard ratio: 2.89; 95% conﬁdence intervals: 1.73 to 4.83; p < 0.0001).
The increased risk of bleeding associated with vitamin K antagonist (VKA) treatment was particularly evident when VKA
was combined with an antiplatelet therapy (APT). In contrast, the risk of cardiovascular death, MI, or nonhemorrhagic
stroke did not differ in patients who received VKA þ APT versus patients on VKA alone.
CONCLUSIONS In patients with stable CAD (i.e., >1 year, with no acute events), major bleeding events are rare, but
such events are an independent predictor of death. When oral anticoagulation is required, concomitant APT should not be
prescribed in the absence of a recent cardiovascular event. (J Am Coll Cardiol 2014;64:1430–6) © 2014 by the
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AB BR E V I A T I O N S
AND ACRONYM S
APT = antiplatelet therapy
BARC = Bleeding Academic
Research Consortium
CAD = coronary artery disease
CIs = conﬁdence intervals
eGFR = estimated glomerular
ﬁltration rate
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1431limited data on the incidence, source, and prognostic
impact of bleeding beyond 1 year of follow-up (i.e., in
patients with stable CAD). However, these patients,
who may be very long past or who may never have
sustained an acute event, constitute the majority of
CAD patients in the outpatient setting. We therefore
designed the present study to assess the importance
of bleeding and its impact on outcomes in patients
with stable CAD who are at least 1 year past any coro-
nary events (any MI or revascularization procedure).SEE PAGE 1437
HR = hazard ratio
MI = myocardial infarction
VKA = vitamin K antagonistMETHODS
POPULATION. The CORONOR (Suivi d’une cohorte de
patients COROnariens stables en region NORd-Pas-de-
Calais) study was a prospective multicenter study that
enrolled 4,184 consecutive outpatients with stable
CAD (9). Patients were prospectively included be-
tween February 1, 2010 and April 30, 2011 by 50 car-
diologists. The cardiologists were selected on the basis
of geographic distribution to provide a representative
sample of the area’s current cardiology practices in
public universities, public institutions, and private
centers. To be eligible for the CORONOR study, each
patient had to fulﬁll the inclusion criteria. There were
no exclusion criteria. This study was approved by the
French medical data protection committee CCTIRS
(Comité consultatif sur le traitement de l’information
en matière de recherche dans le domaine de la santé)
and authorized by the Commission nationale de l’in-
formatique et des libertés for the treatment of personal
health data. All patients consented to the study after
being informed in writing of the study’s objectives
and treatment of data, as well as of their rights to
object, of access, and of rectiﬁcation.
INCLUSION CRITERIA OF THE CORONOR STUDY.
Patients were categorized with stable CAD if they had
documented CAD and were free from any MI and/or
any coronary revascularization (either percutaneous
coronary intervention or coronary artery bypass graft
surgery) for at least 1 year at inclusion. Documented
CAD was deﬁned as all patients with a history of MI,
history of coronary revascularization, and/or the
presence of a coronary stenosis >50% on a coronary
angiogram. To represent the real-life spectrum of
stable CAD, patients with other cardiovascular or
noncardiovascular illnesses or comorbidities were not
excluded from the study.
STUDY DESIGN. Data col lect ion . At the initial visit,
attending physicians prospectively completed the case
record forms, which contained information regarding
demographic and clinical characteristics of thepatients, including usual cardiovascular risk
factors and treatments. During the outpatient
visit, the investigators reviewed the patients’
current drug treatment and entered all pre-
scribed drugs on the case record form.
Objective, follow-up, deﬁnitions, and end-
points. The objectives of this analysis were to
assess the incidence, source, determinants,
and prognostic impact of major bleeding in
patients with stable CAD. A 2-year clinical
follow-up was performed at outpatient visits
or by contacting the general practitioner. We
collected data on death, MI, stroke, and major
bleeding. All clinical events were adjudicated blindly
by 2 investigators, or by 3 investigators in case of
disagreement, according to pre-speciﬁed deﬁnitions.
The cause of death was determined after a detailed
review of the circumstances of death and was classi-
ﬁed as cardiovascular or noncardiovascular. Deaths
from unknown causes were considered cardiovas-
cular. Bleeding events were classiﬁed using the
Bleeding Academic Research Consortium (BARC)
deﬁnition (10). Information on BARC type 1 and 2
bleeds was not available in our registry. Although not
in the BARC deﬁnitions, for the purpose of this study,
we arbitrarily deﬁned major bleeding as all BARC
type $3 events. To assess ischemic risk, a composite
endpoint was deﬁned as cardiovascular death, MI, or
nonhemorrhagic stroke.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Categorical variables are
expressed as absolute numbers and percents. We used
the chi-square test or the Fisher exact test for the com-
parison of categorical variables and the Student un-
paired t test for the comparison of continuous variables
as appropriate. Cumulative event rates were estimated
using the Kaplan-Meier method and compared using
the log-rank test. Cox proportional hazard analyses
were performed to calculate hazard ratios (HRs) and
95% conﬁdence intervals (CIs). For each variable, the
proportional hazards assumption was tested visually
using Kaplan-Meier curves and by examining a plot of
–ln [–ln(survival time)] against the ln(time). In addition,
the proportional hazard was assessed and satisﬁed by
including an interaction time-dependent term in the
multivariable Cox regression analysis. All statistical
analyses were performed using STATA 9.2 software
(STATA Corporation, College Station, Texas). Statistical
signiﬁcance was assumed at p value <0.05.
RESULTS
The baseline characteristics of the patients included
in the CORONOR study have been reported previously
TABLE 1 Baseline Characteristics of the Study Population
All Patients
(n ¼ 4149)
No major
Bleeding
(n ¼ 4098)
Major
Bleeding
(n ¼ 51) p Value
Age, yrs 66.9  11.5 66.8  11.5 73.3  10.1 0.0001
Men 77.8 77.9 72.6 0.359
Body mass index, kg/m2 28.2  5.0 28.2  5.0 28.7  6.8 0.418
Persistent angina at inclusion 7.2 7.1 15.7 0.019
Current smoker 11.4 11.4 15.7 0.333
History of hypertension 60.2 60.0 78.4 0.008
Diabetes mellitus 31.0 30.8 52.9 0.001
Familial history of CAD 27.8 27.8 29.4 0.801
Previous MI 62.4 62.5 60.8 0.806
Previous coronary angiography 99.2 99.2 100.0 0.507
Multivessel CAD 57.2 57.6 74.5 0.015
Previous myocardial revascularization 85.9 86.0 80.4 0.253
Previous bare metal stent 53.0 53.2 43.1 0.155
Previous drug-eluting stent 25.0 24.8 37.2 0.042
Previous coronary bypass 21.3 21.3 17.7 0.523
Previous stroke 7.4 7.4 9.8 0.510
Previous aortic or peripheral intervention 9.4 9.3 19.6 0.012
Previous hospitalization for heart failure 7.5 7.3 27.5 <0.0001
Atrial ﬁbrillation at inclusion 7.2 6.9 31.4 <0.0001
LVEF, % 57.5  10.8 57.6  10.7 51.5  14.3 0.0001
eGFR, ml/min/1.73 m2 79  24.5 79.2  24.4 62.3  24.5 <0.0001
Aspirin 77.0 76.9 84.3 0.211
Clopidogrel 40.3 40.4 29.4 0.111
Aspirin and clopidogrel 20.8 20.9 17.7 0.574
Vitamin K antagonists 11.1 10.7 41.2 <0.0001
ACE inhibitors 59.4 59.3 64.7 0.434
Angiotensin II receptor antagonists 24.1 24 27.5 0.568
Beta-blockers 79.3 79.3 80.4 0.852
Statins 92.2 92.3 82.4 0.008
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; CAD ¼ coronary artery disease; eGFR ¼ estimated glomerular ﬁltration
rate using the MDRD formula; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction.
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1432(9) and are summarized in Table 1. Most patients were
men, with a mean age of 66.9  11.5 years. Most pa-
tients underwent at least 1 coronary revascularization
procedure before inclusion. There was wide pre-
scription of major secondary prevention drugs (i.e.,
beta-blockers, statins, and angiotensin system an-
tagonists). Almost all patients received at least 1
antithrombotic treatment (99.3%). The majority
received antiplatelet therapy (APT) alone (n ¼ 2,798;
67.4%; aspirin, n ¼ 2,025; clopidogrel, n ¼ 773).
Although these patients had no recent coronary
events, a substantial proportion received dual anti-
platelet treatment (i.e., aspirin and clopidogrel;
n ¼ 861; 20.8%). Altogether, 11.1% received a vitamin
K antagonist (VKA). Among these patients, most
(n ¼ 342) received the combination of a VKA and an
antiplatelet agent (VKA þ APT) (aspirin, n ¼ 308;
clopidogrel, n ¼ 34), whereas 119 received a VKA
alone. Of note, no patient received prasugrel, tica-
grelor, or new oral anticoagulants at inclusion.At follow-up, there were 271 deaths (119 cardio-
vascular and 152 noncardiovascular), 91 MIs, and 48
strokes. The combined endpoint of cardiovascular
death, MI, or nonhemorrhagic stroke occurred in 226
patients. There were 51 major bleeding events dur-
ing the 2-year follow-up (0.6 per 100 patient-years).
As shown in Table 2, most events were BARC type
3a bleeds; there were 12 fatal bleeds (type 5). In
most of the cases, the site of bleeding was gastro-
intestinal (54.9%). The site of fatal bleeding was
intracranial in 6 patients, gastrointestinal in 4 pa-
tients, retroperitoneal in 1 patient, and pericardial in
1 patient. Figure 1 illustrates the timing of the
bleeding events and shows that the risk of bleeding
was constant throughout the follow-up. During the
follow-up, 6 additional deaths occurred among the
patients who experienced major bleeding, giving a
total of 18 (35.3%) deaths. The time interval be-
tween the bleeding event and death was 12  19
days for the 12 patients with type 5 bleeding, and
174  142 days in the 6 patients who died after type
3 to 4 bleeding. When used as a time-dependent
variable, major bleeding was associated with a sig-
niﬁcant increase in mortality (unadjusted HR: 6.78;
95% CI: 4.2 to 10.94; p < 0.0001); major bleeding
remained signiﬁcantly associated with mortality
(HR ¼ 2.89; 95% CI 1.73 to 4.83; p < 0.0001) when
adjusted for age, sex, diabetes mellitus, previous
heart failure, and the estimated glomerular ﬁltration
rate (eGFR).
The patients who experienced major bleeding were
older and more frequently had angina, a history of
hypertension, diabetes mellitus, and multivessel
CAD. The patients who bled also more frequently
underwent drug-eluting stent implantation, aortic
or peripheral intervention, were hospitalized for
decompensated heart failure, had a lower left ven-
tricular ejection fraction and eGFR, more often
received VKA, and were less frequently on statin
therapy (Table 1). As shown in Table 3, 4 variables
were identiﬁed as independent predictors of major
bleeding by multivariate analysis: treatment with
VKA, diabetes mellitus, age (positive association),
and eGFR (negative association). The impact of
antithrombotic treatments on the risk of major
bleeding is shown in Figure 2. The increased bleeding
risk associated with VKA treatment was particularly
evident in patients who received the combination of
VKA þ APT, whereas there was no signiﬁcant increase
in bleeding in patients who received VKA alone. In
contrast, as shown in Figure 3, there was no differ-
ence in the risk of the combined endpoint of cardio-
vascular death, MI, or nonhemorrhagic stroke in
patients treated with VKA þ APT versus patients
TABLE 3 Multivariate Predictors of Major Bleeding
Hazard Ratio 95% CI p Value
Vitamin K antagonists 4.69 2.60–8.44 <0.0001
Diabetes mellitus 2.76 1.54–4.96 0.005
Age (per yr) 1.04 1.01–1.08 0.001
eGFR (per ml/min/1.73 m2) 0.98 0.97–0.99 0.008
The variables included in the model were age, history of hypertension, diabetes
mellitus, multivessel coronary artery disease, previous aortic or peripheral inter-
vention, previous hospitalization for heart failure, left ventricular ejection fraction,
estimated glomerular ﬁltration (eGFR) rate, use of vitamin K antagonists, and use
of statins. A stepwise approach was used with forward selection (the p value for
entering into the stepwise model was set at 0.05).
TABLE 2 Major Bleeding Events During the 2-Year
Follow-Up Period
BARC type
3a 21 (41.2)
3b 12 (23.5)
3c 4 (7.8)
4 2 (3.9)
5 12 (23.5)
Bleeding site
Intracranial 10 (19.6)
Gastrointestinal 28 (54.9)
Retroperitoneal 2 (3.9)
Pulmonary 1 (2)
Pericardial 3 (5.9)
Genitourinary 3 (5.9)
Other 4 (7.8)
Values are n (%). Type 3a: overt bleeding plus hemoglobin drop of 3 to <5 g/dl
and/or any transfusion with overt bleeding; type 3b: overt bleeding plus hemo-
globin drop <5 g/dl, cardiac tamponade, bleeding requiring surgical intervention
for control, and/or bleeding requiring intravenous vasoactive agents; type 3c:
intracranial hemorrhage and/or intraocular bleed compromising vision; type 4:
bleeding related to coronary artery bypass graft surgery; type 5: fatal bleeding.
BARC ¼ Bleeding Academic research Consortium (10).
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1433treated with VKA alone (adjusted HR: 1.15; 95% CI:
0.58 to 2.27; p ¼ 0.697).
DISCUSSION
There is now clear evidence that bleeding is a key
event with important prognostic implications in pa-
tients with acute manifestations of CAD (1–3) and in
patients undergoing myocardial revascularization
procedures (4,5). Much less is known regarding
bleeding events that occur in patients with stable1.5
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FIGURE 1 Time Frame for Bleeding Events
BARC classes are detailed in the footnote of Table 2. BARC ¼
Bleeding Academic Research Consortium.and chronic CAD at a chronological distance from any
MI or revascularization. Data from the CHARISMA
(Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance)
trial provided meaningful information on bleeding
rates according to antiplatelet regimens (11). How-
ever, because the patients included in randomized
trials are highly selected (patients who required VKA
or patients believed to be at particularly high risk of
bleeding were excluded from the CHARISMA study),
the ability to extrapolate these results to the overall
stable CAD population is limited. An analysis of
the REACH (Reduction of Atherothrombosis for
Continued Health) registry reported risk factors for
serious bleeding in a large group of outpatients with
various manifestations of atherothrombosis (CAD,
cerebrovascular disease, peripheral arterial diseases)
or with at least 3 atherosclerosis risk factors in 2003
to 2004 (12). However, to the best of our knowledge,
the present study is the ﬁrst to focus on a contem-
porary cohort of patients with stable CAD and the ﬁrst
to provide information on major bleeding in a real-life
setting.
Our results showed that a BARC type $3 bleed is
a relatively rare event in stable CAD patients (0.6%/
patient-year). It is, however, important to point out
that this rate applies to a study population included
in an outpatient setting, and that all patients were
>1 year from a cardiovascular hospitalization for MI
or coronary revascularization at inclusion in the
study. The most frequent ﬁnding was the incidence
of major bleeding episodes related to gastrointes-
tinal bleeding. The data also demonstrated that the
occurrence of major bleeding in a stable CAD pa-
tient was an independent predictor of death. All
physicians following stable CAD patients should,
therefore, pay special attention to the determinants
of bleeding. Several independent risk factors for
major bleeding were identiﬁed. As observed in pa-
tients with unstable CAD (2,13), increasing age,
diabetes, and renal insufﬁciency were associated
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FIGURE 2 Major Bleeding in Stable Coronary Artery Disease Patients According to Antithrombotic Treatments
(A) Kaplan-Meier curves during follow-up. (B) Age- and sex-adjusted hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for major bleeding
in the different groups. The MAPT group served as the reference group. MAPT ¼mono-antiplatelet therapy; DAPT ¼ dual-antiplatelet therapy;
VKA ¼ vitamin K antagonist; VKA þ APT ¼ vitamin K antagonist and antiplatelet therapy.
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1434with an increased risk of bleeding in stable CAD.
Long-term oral anticoagulation was the strongest
risk factor for bleeding in this stable setting; in
particular, we found that the combination of oral
anticoagulation with an antiplatelet agent was0
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FIGURE 3 Cardiovascular Death, Myocardial Infarction,
or Nonhemorrhagic Stroke in Stable Coronary Artery
Disease Patients Treated With Vitamin K Antagonists
According to Antiplatelet Use
Kaplan-Meier curves with hazard ratios (HRs) during follow-up.
HR (95% conﬁdence interval) for VKA þ APT versus VKA alone.
*Analyses were adjusted for age, sex, diabetes mellitus, previous
heart failure, and estimated glomerular ﬁltration rate. Abbrevi-
ations as in Figure 2.associated with a major increase in the number of
bleeding episodes.
A signiﬁcant proportion of patients with stable
CAD are treated with oral anticoagulation (>10% in
the present study), mainly because of atrial ﬁbrilla-
tion. Although common practice is to treat such pa-
tients with VKA þ 1 APT drug (usually aspirin), the
2010 European Society of Cardiology guidelines on
atrial ﬁbrillation suggest that, in patients with stable
vascular disease (i.e., >1 year with no acute events),
VKA monotherapy may be considered, and that in
the absence of a subsequent cardiovascular event,
concomitant APT should not be prescribed (14). This
was on the basis of evidence that the addition of an
APT is associated with a substantial increase in
bleeding, with no clear evidence for a decrease in
ischemic events (15–17). It should be noted, however,
that data in patients with stable CAD and modern
management (i.e., wide use of coronary revasculari-
zation, including drug-eluting stent implantation)
were lacking. The American College of Cardiology
and the American Heart Association endorsed a
similar statement (18). Recruitment in the present
study was performed at the time these guidelines
were released. We observed that three-quarters of
patients who received a VKA were also treated
with an antiplatelet agent; this is concordant
with the recent EuroObservational Research Pro-
gramme Atrial Fibrillation Pilot Registry report, in
which APT was still commonly prescribed with oral
CENTRAL ILLUSTRATION Major Bleeding in Stable CAD
Although major bleeding is rare in patients with stable coronary artery disease (CAD), its incidence is increased in patients who receive oral
anticoagulation and antiplatelet therapy. Major bleeding is an independent predictor of death in stable CAD.
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1435anticoagulation when there was coexistent CAD (19).
This illustrates that physicians remain hesitant to
stop all APTs in stable CAD patients who need oral
anticoagulation. However, our follow-up data sug-
gest that this attitude leads to an increased risk of
bleeding that does not appear to be balanced by a
concomitant decrease in the risk of ischemic
complications.
STUDY LIMITATIONS. Our data reﬂect the practice in a
regional area in 2010 to 2011. Although this was not a
population-based registry, the patients included were
treated at research institutions and smaller commu-
nity hospitals, as well as in private practice. It will have
to be determined whether these ﬁndings are repre-
sentative of practices in other parts of the world, and
how these trends could change in the era of new drug-
eluting stents that lower the risk of thrombosis. In the
present study, anticoagulant therapy was limited to
VKA, and antiplatelet agents were limited to aspirin
and/or clopidogrel; therefore, our results cannot be
directly extrapolated to novel oral anticoagulants
and antiplatelet agents. In addition, our study only
focused on BARC $3 bleeds; thus, less severe events
that could be associated with prognosis were not
analyzed. Further studies are needed to clarify the
association of the different BARC classes with out-
comes in the outpatient setting, as was recently re-
ported for patients with ST-segment elevation MI (20).
As with any observational study, the association
between treatment and outcomes cannot provecausality. The limitation of adjustment methodology
is also acknowledged, and persistent unknown or
unmeasured confounding factors may exist. Finally,
we also acknowledge that our study had limited
power to compare patients receiving VKA alone with
patients receiving VKA þ APT.CONCLUSIONS
In patients with stable CAD, major bleeding events
are rare, but they are an independent predictor of
death (Central Illustration). When oral anticoagulation
is required, the use of concomitant APT is associated
with an important increase in bleeding, with no evi-
dence of a decrease in ischemic events. For the
clinician, the important message is to avoid long-term
use of antiplatelet agents in combination with oral
anticoagulation in stable CAD patients, and to
consider co-prescription of a proton-pump inhibitor
because many events in these patients are related to
gastrointestinal bleeding. Lastly, it should be
emphasized that our ﬁndings should not be extrapo-
lated to patients within 1 year of MI or coronary
revascularization.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Anti-
platelet drugs increase the risk of bleeding, but have little
or no impact on the risk of ischemic events in patients
with CAD who receive chronic anticoagulation and who
have not experienced an acute ischemic event or under-
gone revascularization for >1 year. Major bleeding occurs
rarely in patients with stable ischemic heart disease, but it
does have important prognostic implications for mortality.
TRANSLATIONAL OUTLOOK: The relative risks and
beneﬁts of prolonged APT should be periodically reas-
sessed in patients with stable ischemic heart disease
who receive chronic anticoagulation, and additional
studies are needed to delineate predictors of adverse
outcomes.
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